IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+11.71%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$302M
AUM Growth
+$302M
(-1.5%)
Cap. Flow
-$35.1M
Cap. Flow
% of AUM
-11.6%
Top 10 Holdings %
Top 10 Hldgs %
44.95%
Holding
160
New
20
Increased
14
Reduced
32
Closed
33
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$10.5M |
| 2 |
Apogee Therapeutics
APGE
|
$10.1M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$8.15M |
| 4 |
Insmed
INSM
|
$7.95M |
| 5 |
Cogent Biosciences
COGT
|
$7.44M |
Top Sells
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 2 |
Tarsus Pharmaceuticals
TARS
|
$11.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$10.1M |
| 4 |
Lyra Therapeutics
LYRA
|
$9.29M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$7.86M |
Sector Composition
| 1 | Healthcare | 99.76% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
NewAmsterdam Pharma
NAMS
$2.71B
| $3.75M | 0.72% |
+206,800
| New | +$3.75M |
|
27
Dyne Therapeutics
DYN
$1.92B
| $3.46M | 0.67% |
363,837
+5,000
| +1% | +$47.6K |
|
|
TECX
28
Tectonic Therapeutic, Inc. Common Stock
TECX
$312M
| $3.25M | 0.62% |
163,696
-105,394
| -39% | -$2.09M |
|
|
MAZE
29
Maze Therapeutics, Inc. Common Stock
MAZE
$635M
| $3.22M | 0.62% |
262,740
-60,000
| -19% | -$736K |
|
30
Janux Therapeutics
JANX
$1.37B
| $3M | 0.58% |
129,691
| – | – |
|
31
Fulcrum Therapeutics
FULC
$351M
| $2.95M | 0.57% |
428,521
+228,425
| +114% | +$1.57M |
|
32
Eledon Pharmaceuticals
ELDN
$155M
| $2.71M | 0.52% |
1,000,221
-25,000
| -2% | -$67.8K |
|
33
Biogen
BIIB
$19.4B
| $2.7M | 0.52% |
+21,516
| New | +$2.7M |
|
34
Viking Therapeutics
VKTX
$3.09B
| $2.65M | 0.51% |
100,000
+50,000
| +100% | +$1.33M |
|
35
Relay Therapeutics
RLAY
$619M
| $2.57M | 0.49% |
743,308
| – | – |
|
36
Arcturus Therapeutics
ARCT
$462M
| $2.28M | 0.44% |
175,000
| – | – |
|
37
Geron
GERN
$893M
| $2.26M | 0.43% |
1,600,000
+1,450,000
| +967% | +$2.04M |
|
38
KalVista Pharmaceuticals
KALV
$678M
| $2.24M | 0.43% |
+198,528
| New | +$2.24M |
|
39
Kodiak Sciences
KOD
$478M
| $2.24M | 0.43% |
599,534
-50,000
| -8% | -$187K |
|
40
Lexeo Therapeutics
LXEO
$259M
| $2.21M | 0.42% |
550,029
| – | – |
|
|
MTSR
41
Metsera, Inc. Common Stock
MTSR
$3.8B
| $2.2M | 0.42% |
77,316
-72,684
| -48% | -$2.07M |
|
42
Ventyx Biosciences
VTYX
$171M
| $2.07M | 0.4% |
967,590
-250,000
| -21% | -$535K |
|
43
Cumberland Pharmaceuticals
CPIX
$52.2M
| $2M | 0.38% |
595,932
-144,068
| -19% | -$483K |
|
44
ProQR Therapeutics
PRQR
$237M
| $1.77M | 0.34% |
+868,069
| New | +$1.77M |
|
45
Scholar Rock
SRRK
$3.14B
| $1.74M | 0.33% |
49,179
-195,000
| -80% | -$6.91M |
|
|
DRUG
46
Bright Minds Biosciences
DRUG
$276M
| $1.71M | 0.33% |
65,431
| – | – |
|
47
uniQure
QURE
$896M
| $1.67M | 0.32% |
+119,986
| New | +$1.67M |
|
|
SLN
48
Silence Therapeutics
SLN
$227M
| $1.4M | 0.27% |
+873,568
| New | +$1.4M |
|
49
Arcus Biosciences
RCUS
$1.13B
| $1.33M | 0.26% |
163,363
| – | – |
|
50
Apellis Pharmaceuticals
APLS
$3.48B
| $1.3M | 0.25% |
75,000
| – | – |
|